glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Coach Gary Miller on Retatrutide: His Protocol vs What the Data Shows

Part of YouTube & Expert Fact Checks.

Coach Gary Miller on Retatrutide: His Protocol vs What the Data Shows

Powerbuilding coach Gary Miller published a May 2025 video titled "Retrutide or GLP-3 for fat loss and muscle retention!" presenting retatrutide as "probably one of the most powerful peptides for body recomposition we've ever seen." After 35 years of personal training and 25 years coaching, Miller offers a suggested protocol combining retatrutide with strength training, high-protein nutrition, and a peptide stack.
This page checks his claims and protocol recommendations against published clinical trial data. Miller states upfront that he is not a doctor and that the video is for educational purposes only.

His Top Claims: Fact Check

Miller lists four key benefits of retatrutide. Here is how each compares to published data:

ClaimPublished DataVerdict
20 to 30 pounds of fat loss in clinical trialsTRIUMPH-4 later reported 71.2 lb of total body-weight loss at 12 mg over 68 weeks. Total weight is not fat mass, and that result postdates the video.Not comparable: fat mass versus total weight
Targets deep visceral fatMRI data show substantial liver-fat reduction; liver fat and visceral adipose tissue are different measures. The trial does not establish selective targeting.Needs a specific body-composition endpoint
Stronger appetite suppression than semaglutide or tirzepatideNo head-to-head appetite comparison exists; weight loss data suggests greater effectPlausible but unproven
Muscle preservation when paired with protein and trainingThe published DXA substudy studied adults with type 2 diabetes at 36 weeks. It did not test Miller’s training-and-protein protocol or establish superiority over another drug.Overstated — not uniquely muscle-sparing
Enhances resting energy expenditureGlucagon receptor activation increases energy expenditure in preclinical dataPreclinical support, not a quantified human effect

The main distinction is fat loss versus total weight loss. Miller’s 20–30 lb claim is not disproved by a later 71.2 lb total-weight result. His May 2025 video also predates TRIUMPH-4’s December 2025 announcement. A valid fact-check needs the same endpoint and evidence available at the time.

For the full trial data, see Retatrutide Results. For the mechanism, see What Is Retatrutide.

His Suggested Protocol

Miller recommends the following:

  • Starting dose: 2.5mg weekly (or as low as 1mg)
  • Target dose: "7 and 12 to 10 milligrams per week"
  • Administration: Subcutaneous, once weekly
  • Nutrition: High protein, low inflammatory
  • Training: Lift weights 4 times per week
  • Cardio: Daily walking, 8,000–10,000 steps
  • Peptide stack: Tesamorelin, TB-500, BPC-157 and other peptides
ElementHis RecommendationClinical Trial Protocol
Starting dose2.5 mg (or 1 mg)2 mg in Phase 3 TRIUMPH program
Target dose7–12 mg4, 9 or 12 mg in TRIUMPH-1; 9 or 12 mg in TRIUMPH-4
Titration speedNot specifiedEvery 4 weeks: 2 → 4 → 6 → 9 → 12
Peptide stackingTesamorelin, TB-500, BPC-157 and other peptidesNot studied — no data on combinations
Exercise requirement4x/week weights + daily walkingLifestyle modification counseling in trials

The recommendation is not a validated treatment protocol. TRIUMPH-4 used a 2 mg starting dose and four-week escalation intervals, while other studies included other target groups. His target-dose wording is unclear in the retrieved transcript and should not be converted into a precise regimen. Lower starting doses reduced gastrointestinal events in Phase 2; that does not establish that “skipping steps” caused every discontinuation.

His peptide stack recommendation (tesamorelin, TB-500, BPC-157 and other peptides) has no clinical evidence when combined with retatrutide. The safety profile of these combinations is unknown.
For clinical dosing guidance, see Retatrutide Dosage. For the titration schedule, see Retatrutide Dosing Schedule.

The "Metabolic Reboot" Claim

Miller describes retatrutide as providing a "metabolic reboot" — enhancing insulin sensitivity, glucose regulation, and resting energy expenditure. He suggests it is a "game changer for those who think they have a slow metabolism."

Retatrutide has improved HbA1c in trials involving type 2 diabetes, but HbA1c is a measure of glycemic control, not a direct measurement of insulin sensitivity. Preclinical energy-expenditure findings do not demonstrate a human “metabolic reboot” or a durable reset after stopping.

For diabetes-specific data, see Retatrutide for Diabetes.

Frequently Asked Questions

Who is Gary Miller?

Gary Miller is a powerbuilding coach who runs Gary Miller Fitness. He describes himself as having 35 years of personal training experience and 25 years coaching athletes and professionals. He is not a physician or medical researcher. His retatrutide video presents a suggested protocol based on his coaching experience.

Is his protocol safe to follow?

There is no published trial validating this proposed retatrutide and peptide-stack regimen. Its risks cannot be resolved simply by matching a starting dose or adding monitoring. Retatrutide remains investigational; trial participants should use their study team’s instructions.

Did he understate the weight loss results?

That verdict was not justified. Miller discussed 20–30 lb of fat loss; TRIUMPH-4 later reported 71.2 lb of total body-weight loss. Those are different outcomes, and TRIUMPH-4 was announced after his May 2025 video. The named trial, dose and body-composition endpoint are needed to verify his claim.

Does retatrutide actually preserve muscle?

Retatrutide’s published DXA substudy in type 2 diabetes measured fat and lean mass over 36 weeks. It did not show that Miller’s proposed protein-and-training regimen prevents muscle loss or that retatrutide preserves muscle better than another medicine. Lean mass also includes tissue other than skeletal muscle.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all fact checks topics →